Robert Engler

Robert Engler is a declared insider of Halozyme Therapeutics, Inc., with filings sourced from SEC (Form 4). The record holds 22 filings, for trades running from 4 May 2006 to 14 August 2014.

Both buying and selling appear: 3 purchases worth €125k, against 8 sales worth €1.1M. Taken together, the sales exceed the purchases by €986k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 9 share grants and 2 option exercises. 2014 to date brings no purchases and 2 sales.

Half of the purchases are above €31k and half below. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -12.5%. This is a record of the past, not a forecast.

Most recently, on 18 August 2014, the filings show an option exercise worth €115k in Halozyme Therapeutics, Inc. The latest purchase dates back some time: it was published 5,093 days ago, on 29 November 2012. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.